Radiotherapy for ductal carcinoma in situ

Clinical Oncology

Volumn 18, Issue 3, 2006, Pages 179-184

  Adlard, J W ^a   Bundred, N J ^b  

^a Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Breast; DCIS; Ductal carcinoma in situ; Radiotherapy

Indexed keywords

TAMOXIFEN;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SCREENING; CARCINOMA IN SITU; CLINICAL TRIAL; DISEASE CONTROL; ERYTHEMA; FEMALE; HUMAN; LETHARGY; MAMMOGRAPHY; MASTECTOMY; ORGAN PRESERVATION; PAGET NIPPLE DISEASE; PRIORITY JOURNAL; PUBLICATION; RELIABILITY; REVIEW; RISK FACTOR;

EID: 33144460208     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2005.11.002     Document Type: Article

References (37)

1. J.R. Toms CancerStats monograph 2004: Cancer incidence, survival and mortality in the UK and EU 2004 Cancer Research UK London 31-36
2. L.C. Collins R.M. Tamimi H.J. Baer J.L. Connolly G.A. Colditz S.J. Schnitt Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy Cancer 103 2005 1778-1784
3. M.E. Sanders P.A. Schuyler W.D. Dupont D.L. Page The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long term follow up Cancer 103 2005 2481-2484
4. B. Fisher C. Redmond R. Poisson et. al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer N Engl J Med 320 1989 822-828
5. M.J. Silverstein A. Barth D.N. Poller et. al. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast Eur J Cancer 31A 1995 1425-1427
6. J. Boyages G. Delaney R. Taylor Predictors of local recurrence after treatment of ductal carcinoma in situ: A meta-analysis Cancer 85 1999 616-628
7. B. Fisher S. Land E. Mamounas J. Dignam E.R. Fisher N. Wolmark Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience Semin Oncol 28 2001 400-418
8. J.P. Julien N. Bijker I.S. Fentiman et. al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group Lancet 355 2000 528-533
9. J. Houghton W.D. George J. Cuzick C. Duggan I.S. Fentiman M. Spittle Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial Lancet 362 2003 95-102
10. M.J. Silverstein M.D. Lagios Benefits of irradiation for DCIS: A Pyrrhic victory Lancet 355 2000 510-511
11. N.N. Baxter B.A. Virnig S.B. Durham T.M. Tuttle Radiation after lumpectomy for DCIS to reduce the risk of invasive breast cancer: A population-based study [abstract 516] Proc Am Soc Clin Oncol 2005
12. E.R. Fisher J. Dignam E. Tan-Chiu et. al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: Intraductal carcinoma Cancer 86 1999 429-438
13. N. Bijker J.L. Peterse L. Duchateau et. al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European Organization for Research and Treatment of Cancer Trial 10853 J Clin Oncol 19 2001 2263-2271
14. R. Holland J. Hendriks A.L.M. Verbeek M. Mravunac J.H. Schuurmans Stekhoven Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ Lancet 335 1990 519-522
15. D.E. Wazer R.K. Schmidt-Ullrich R. Ruthazer et. al. The influence of age and extensive intraductal component histology upon breast lumpectomy margin assessment as a predictor of residual tumour Int J Radiat Oncol Biol Phys 45 1999 885-891
16. S.K. Al-Ghazal R.W. Blamey Cosmetic assessment of breast conserving surgery for primary breast cancer Breast 8 1998 162-168
17. S. Pinder E. Ellis J. Houghton J. Cuzick C. Duggan W. George Histopathological review of the UK DCIS trial of radiotherapy and tamoxifen following complete excision for localised disease [abstract 609A] Proc Am Soc Clin Oncol 2000
18. M.J. Silverstein M.D. Lagios S. Groshen et. al. The influence of margin width on local control of ductal carcinoma in situ of the breast N Engl J Med 340 1999 1455-1461
19. G.P. Boland K.C. Chan W.F. Knox S.A. Roberts N.J. Bundred Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast conserving surgery Br J Surg 90 2003 426-432
20. M.J. Silverstein M.D. Lagios P.H. Craig et. al. A prognostic index for ductal carcinoma in situ of the breast Cancer 77 1996 2267-2274
21. M.J. Silverstein The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast Am J Surg 186 2003 337-343
22. G.F. Schwartz L.J. Solin I.A.O. Olivotto et. al. The consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22-25, 1999 Cancer 88 2000 946-954
23. F. Meric T.A. Buchholz N.Q. Mirza et. al. Long term complications associated with breast conservation surgery and radiotherapy Ann Surg Oncol 9 2002 543-549
24. Allred D, Bryant J, Land S, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: Findings from NSABP Protocol B-24 [abstract 30]. San Antonio Breast Cancer Symposium, 2002.
25. R.R. Millis L.G. Bobrow D.M. Barnes Immunohistochemical evaluation of biological markers in mammary carcinoma in situ: Correlation with morphological features and recently proposed schemes for histological classification Breast 5 1996 113-122
26. G.P. Boland A. McKeown K.C. Chan R. Prasad W.F. Knox N.J. Bundred Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast Br J Cancer 89 2003 277-283
27. M.E. Bur M.J. Ximarowski S.J. Schnitt S. Baker R. Lew Oestrogen receptor immunohistochemistry in carcinoma in situ of the breast Cancer 69 1992 1174-1181
28. G.L. Ottesen I.J. Christensen J.K. Larsen et. al. Carcinoma in situ of the breast: Correlation of histopathology immunohistochemical markers and DNA ploidy Breast Cancer Res Treat 60 2000 219-226
29. A. Gandhi P.A. Holland W.F. Knox et. al. Effects of a pure antioestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ Cancer Res 60 2000 4284-4288
30. B. Fisher J. Dignam N. Wolmark et. al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B24 randomised controlled trial Lancet 353 1999 1993-2000
31. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials Lancet 365 2005 1687-1717
32. ATAC Trialist's Group Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60-62
33. Investigators. DCIS II trial. Final protocol Version 3, 2004.
34. H. Yamauchi V. Steamo D.F. Hayes When is a tumour marker ready for prime time? A study of CerbB2 as a predictive factor in breast cancer J Clin Oncol 19 2001 2334-2356
35. J. Bonneterre A. Buzdar J.M. Nabholtz et. al. Anastrazole (Arimidex) is superior to tamoxifen as first line therapy in hormone receptor-positive advanced breast cancer Cancer 92 2001 2247-2258
36. M.J. Ellis A. Coop B. Singh et. al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2 positive, estrogen receptor positive primary breast cancer: Evidence from a phase III randomized trial J Clin Oncol 19 2001 3795-3797
37. C.C. Benz G.K. Scott J.C. Sarup et. al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF7 cells transfected with HER2/neu Breast Cancer Res Treat 24 1993 85-95